These results identify FD as a putative tumor cell-associated biomarker and therapeutic target of cSCC and, for the first time, introduce the small-molecule FD inhibitor danicopan as a highly sensitive and specific drug in precision cancer therapy (Figure 6). Here, ELP1 is linked to cancer.